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Objective: To explore differences in response to a low dosage regimen of infliximab with an 
escalating dosage in comparison to a standard dosage of etanercept and adalimumab in patients 
with psoriatic arthritis (PsA).
Methods: Biologically naïve PsA patients who were beginning anti-TNF-α therapy were selected 
from the ICEBIO registry. Demographics and clinical differences were compared in four treat-
ment groups: infliximab <4 mg/kg; infliximab >4 mg/kg; etanercept or  adalimumab at baseline 
and on follow-up (6 and 12 months, last visit). The Kruskal–Wallis rank sum test was used for 
comparison of the groups and the Wilcoxon test to compare the two infliximab dosage regimens.
Results: One hundred and eighty-five patients (61% female) were identified; 84 patients received 
infliximab, 66 etanercept, and 35 adalimumab. A total of 19% of the patients treated with infliximab 
escalated their dosage ≥4 mg/kg. No significant differences were observed at baseline in respect 
to visual analog scale (VAS) pain, VAS fatigue, Health Assessment Questionnaire, C-reactive 
protein (CRP), numbers of swollen or tender joints, or Disease Activity Score (DAS) 28-CRP 
values. A similar treatment response was observed in all four treatment groups on follow-up. 
Conclusion: In respect to treatment effects, a low dosage of infliximab with possible escalating 
dosage is acceptable for the majority of PsA patients who are in need of biological treatment. 
Keywords: psoriatic arthritis, outcome, biological treatment, routine care, clinical nationwide 
registry
Introduction 
The prevalence of psoriatic arthritis (PsA) in Iceland is at least 0.14%-0.19% accord-
ing to a recent publication from the Reykjavik Psoriatic Arthritis study, where the 
clinical manifestations are also described.1 International guidelines on the treatment 
strategies for PsA have been published both by EULAR (European League Against 
Rheumatism)2 and GRAPPA (Group for Research and Assessment of Psoriasis and 
Psoriatic Arthritis).3 Similar guidelines have been published nationally, e.g., in Ice-
land.4 Although these guidelines are very similar, there is a major difference in the 
Icelandic version in respect to the dosage of infliximab, i.e., the Icelandic guideline 
recommends an infliximab dosage of 200 mg given on weeks 0, 2, 6, and then every 
8th week, independently of body weight, with possible escalating dosage as needed 
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according to clinical response, while most other guidelines 
recommend infliximab dosage of 5 mg/kg. Other TNF inhibi-
tors are given in fixed standard dosages.
The IMPACT (Infliximab Multinational Psoriatic Arthritis 
Controlled Trial) and the IMPACT2 trials, which both focused 
on patients with PsA, used protocols with 5 and 10 mg/
kg of infliximab,5,6 whereas previously a trial of infliximab 
in patients with psoriasis used 3 and 5 mg/kg.7 Therefore, 
international guidelines recommend the dosage of infliximab 
to be 5 mg/kg. Meanwhile, no randomized controlled stud-
ies on lower dosages have been published for PsA. However, 
scattered case reports reported using a lower dosage and a 
small series of patients with PsA have been treated with a 
lower dosage or 3 mg/kg, i.e., according to recommendations 
for rheumatoid arthritis (RA).8–10 Cauza et al reported nine 
patients with PsA and psoriasis vulgaris who received 3 mg/
kg of infliximab, which was effective and well tolerated.8 In 
2009 Di Renzo et al asked why 3 mg/kg instead of 5 mg/kg 
of infliximab should not work in PsA and he also reported a 
case of a 38-year-old white man with body weight of 104 kg, 
affected by plaque-type psoriasis and PsA, who responded 
well to 3 mg/kg of infliximab.9 Recently, Tenga et al reported 
their retrospective experience of starting 3 mg/kg in ten 
patients with spondyloarthritis in association with PsA.10 
Furthermore, we have, together with the Danish database 
DANBIO, recently published that starting at a dose lower 
then 4 mg/kg of infliximab did not affect drug survival or 
treatment response in patients with PsA.11 In addition, several 
reports on a similar treatment regime have been published in 
ankylosing spondylitis (AS).12,13 Still, international guidelines 
recommend a dosage of infliximab 5 mg/kg for AS, as for PsA. 
By using data from ICEBIO, a nationwide registry on 
routine use of biologics for rheumatic disorders in Iceland, 
we aim to explore differences in response to a low dosage 
regimen of infliximab with escalating dosage in compari-
son to a standard dosage of etanercept and adalimumab in 
patients with PsA.
Material and methods 
Patients with PsA who were all biologically naïve and initiating 
their first anti-TNF-α therapy were selected from the ICEBIO 
registry. However, most of the patients have been treated with 
methotrexate or other disease modifying drugs before the start 
of their biologic therapy, but they were naïve for biologics.
ICEBIO is an Icelandic nationwide database on patients 
treated with biologic disease-modifying antirheumatic drugs 
due to inflammatory joint diseases; including RA, AS, and 
PsA. The database is based on the Danish Registry for 
Biologic Therapies in Rheumatology, DANBIO.14 ICEBIO 
started collecting data in 2007 with a prospective registration 
at initiation of all biologics, as well as on annual follow-up 
visits. Patients who started their treatment before 2007 have 
been registered retrospectively in ICEBIO based on their 
medical records. Currently, ICEBIO covers approximately 
98% of all patients treated with biologics for rheumatic 
disorders in Iceland. On January 1, 2015, there was informa-
tion available on 953 individuals in ICEBIO, of whom 222 
individuals had been diagnosed with PsA.
When patients start treatment with biologics in Iceland, it 
is obligatory to register detailed health and disease informa-
tion in ICEBIO, regardless of whether the treating physician is 
at the university hospital or at his/her private clinic. Standard 
follow-up data are then registered annually on regular visits 
to outpatient clinics. ICEBIO is part of the patient electronic 
record system, hosted by the University Hospital of Iceland. 
Thus, it is independent from the pharmaceutical industry. 
As a standard of care, the startup dosage of infliximab was 
200 mg on weeks 0, 2, 4, and then every 8th week, indepen-
dently of the body weight of the patient. Insufficient response 
to treatment resulted the dosage was increased stepwise by 
100 mg, e.g., up to 300 mg, or 400 mg. If the dosage reached 
4 mg/kg the patient was classified as having a “regular” dos-
age of infliximab in contrast to a low dosage regimen. Other 
TNF inhibitors (etanercept at 50 mg/week and adalimumab 
at 40 mg/2 weeks) were given in fixed dosages.
Demographics include age, gender, disease duration (time 
from confirmed diagnosis of PsA by rheumatologist and the 
time from the start of any symptoms that the individual patient 
claims that is due to his/her PsA) and current treatment with 
methotrexate. Functional status was monitored by Health 
Assessment Questionnaire (HAQ), swollen and tender 28-joint 
count (SJC; TJC), Disease Activity Score (DAS) 28, CRP 
level (normal range ≤10 mg/L), and visual analog scale (VAS) 
for scores of pain and fatigue were collected from ICEBIO. 
Clinical differences were compared in four groups: 
1) those who responded to a low dosage of infliximab (< 4 
mg/kg); 2) those who needed to increase the dosage of inf-
liximab above 4 mg/kg; 3) those who received a standard 
fixed dosage of etanercept  (50 mg/week); or 4) adalimumab 
(40 mg/2 weeks). Follow-up data at 26 weeks (18–32 weeks) 
and 52 weeks (46–64 weeks) weeks were compared and also 
at the last visit at our outpatient clinic (147 weeks; [45–217 
weeks]) after initiating the treatment. 
Data are presented as the mean with 25% and 75% 
quartiles. The Kruskal–Wallis rank sum test was used for 
comparison of the groups and the Wilcoxon test was used to 
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compare the two infliximab dosage regimens. To compare 
drug survival between the groups we used survdiff from 
R version 3.4.3 (R Foundation for Statistical Computing, 
Vienna, Austria). The National Bioethics Committee and 
the Data Protection Authority in Iceland approved the study 
protocol.
Results 
A total of 185 patients, 113 women and 72 men, were identi-
fied; 84 patients received infliximab, 66 etanercept, and 35 
adalimumab (Table 1). No biosimilar TNF inhibitors were in 
use in Iceland at the time of the study. Standard data were col-
lected from ICEBIO from all patients at the start-up of their 
TNF inhibitor treatment, around 6 and 12 months follow-up, 
and then from their latest visit to outpatient clinics, both at the 
University Hospital as well as at private clinics, respectively.
The mean numbers of days (with 25% and 75% quartiles) 
from the start of TNF therapy to the last visit for the group of 
patients that received low dosage of infliximab was 1029 days 
(313; 1366), for those who needed to increase the dosage of 
infliximab, 1363 days (408; 2162), for the etanercept group, 
1040 days (290; 1533), and for the fourth group that received 
adalimumab the number of days to the last visit was 967 (473; 
1386), which did not reach significant differences between 
the groups (Kruskal–Wallis rank sum test,  p-value 0.65). 
Twenty percent of the patients (17/84) treated with inflix-
imab had to escalate the infliximab dosage to exceed 4 mg/kg. 
Those still on a low dosage regimen had a mean dosage of 
infliximab of 2.9 mg/kg, but those who had escalated their 
dosage above 4 mg/kg had a mean dosage of 4.5 mg/kg. Six 
patients required infliximab more frequently than at 8-week 
intervals; five patients (two patients: 200 mg; three patients: 
300 mg) received infliximab at 6-week intervals and one 
patient (300 mg) on a 7-week schedule. 
At baseline those who continued with a low dosage of 
infliximab had a shorter disease duration (8 vs. 10 years), 
but a longer history of symptoms than those who needed to 
increase their dosage of infliximab, but neither value reached 
a significant difference. The patients on a low dosage of 
infliximab had a significantly higher body mass index than 
those on a higher dosage (Wilcoxon test, p<0.01).
No significant differences were observed between the four 
groups at baseline in respect to SJC or TJC, HAQ, VAS pain, 
VAS fatigue or DAS28CRP values, neither at 26, 52 nor on 
the last visit (Table 2). Furthermore, we analyzed the delta 
value of previously-mentioned valuables for each group and 
they did not demonstrate any significant difference between 
the groups (Table 3).
The adherence to treatment after 52 weeks was highest 
in the adalimumab group or 84%, followed by the higher 
infliximab dose group – 81%, etanercept – 75%, and then 
the lower infliximab dose group – 68%, however, it did not 
reach significant difference, not at 52 weeks (p-value 0.31) 
nor at 104 weeks (p-value 0.14). Further, Figure 1 illustrates 
the drug survival time for the groups over a 2-year period.
Discussion
This nationwide, registry-based observational study included 
185 patients with PsA who were all naïve for TNF inhibitors, 
but were in need of biological therapy due to active joint 
disease. The observation time was up to 4 years. The study 
indicates that in respect of treatment efficacy, a low dosage of 
infliximab, with starting dosage of 2.3 mg/kg with possible 
escalating dosage is acceptable for the majority of patients 
with PsA who are in need of biological treatment, and this 
regime seems as effective, in daily clinical practice, as treat-
ment with other TNF inhibitors.
Although international guidelines recommend 5 mg/kg of 
infliximab for patients with PsA, registry studies have dem-
onstrated that in routine care physicians seem to use a lower 
dosage of infliximab; e.g., a report from Sweden  illustrates 
that the starting dose of 3 mg/kg15 gave good treatment 
Table 1 Baseline demographic data
Infliximab
<4 mg/kg
Infliximab
>4 mg/kg
Etanercept
50 mg/week
Adalimumab
40 mg/2 weeks
p-value  between 
the groups**
Number 67 17 66 35
Male, n (%) 30 (41) 8 (47) 23 (35) 13 (37) 0.8004
Age, years 49 (40–56) 49 (38–60) 50 (42–59) 52 (44–60) 0.7741
Disease duration, years 8 (2–13) 10 (3–18) 10 (3–14) 9 (2–11) 0.4343
Symptom duration, years 28 (3–17) 17 (3–28) 11 (5–16) 11 (4–15) 0.9135
BMI, kg/m2 31 (27–34)* 27 (24–29)* 32 (27–36) 30 (26–33) 0.0129
Methotrexate, % 38 40 39 41 0.72
Notes: One hundred and eighty-five patients with psoriatic arthritis, all biologically naïve, who were treated with four different treatment strategies with TNF-α inhibitors. 
Data are presented with means and quartiles. Significant differences were observed in BMI between the two infliximab groups (Wilcoxon test: *p<0.0051). **Kruskal–Wallis 
rank sum test was used to compare all four groups
Abbreviation: BMI, body mass index. 
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results, as does our study in collaboration with DANBIO 
where we demonstrated that a starting dose of 3.1 mg/kg had 
a favorable outcome.11 In the present study, only 20% of the 
patients needed to increase their doses of infliximab above 
4 mg/kg and only a few individuals needed a higher dose than 
the recommended dose of 5 mg per kg body weight. There 
was no standard definition of lack of efficacy which would 
necessitate increased dosage of infliximab, but the individual 
rheumatologist together with the respective patient assumed 
that a higher dosage could benefit the patient, whether that 
decision was made on joint or skin status of the disease, we 
do not have information on. Thus, if a low dose treatment 
schedule with infliximab is as effective as 5 mg/kg, this gives 
rise to a serious discussion of the more economical, though 
still effective, dosage required.
In Iceland, 1-year treatment with etanercept and adali-
mumab costs approximately €12–14.000, while the yearly 
cost of the present treatment schedule of infliximab fixed 
Table 2 Disease activity
Nr CRP mg/L SJC TJC HAQ VAS pain VAS fatigue DAS28
Infliximab
<4 mg/kg
Baseline 59 11.0
3; 16
4.2
1; 6
5.1
2; 6
0.94
0.4; 1.4
62
48; 80
61
45; 83
4.18
3.7; 4.9
26 weeks 34 7.0
3; 6
1.5
0; 3
2.7
0; 5
0.57
0.1; 0.9
36
18; 53
41
20; 60
3.09
2.2; 3.8
52 weeks 18 8.0
3; 11
0.9
0; 1
2.2
0; 3
0.62
0.1; 1.0
43
16; 78
49
25; 70
3.1
2.0; 3.9
Last visit 57 6.6
2; 8
0.7
0; 1
1.9
0; 3
0.69
0.2; 1.0
35
13; 57
39
16; 65
2.77
2.0; 3.4
>4 mg/kg
Baseline 11 11.2
3; 14
3.3
0; 7
8.9
3; 16
1.09
0.4; 1.9
71
60; 87
74
74; 87
4.49
3.7; 5.2
26 weeks  7 8.0
3; 9
1
0; 1
5.4
0; 7
0.84
0.6; 1.1
57
33; 75
50
37; 68
3.47
2.4; 4.0
52 weeks 2 5
4; 8
0
0; 0
1
1; 2
0.38
0.4; 0.4
31
18; 42
30
19; 40
2.2
1.9; 2.4
Last visit 16 5.1
2; 8
0.6
0; 0.3
2.6
0; 3
0.83
0.3; 1.3
41
22; 63
43
20; 67
2.9
2.0; 3.5
Etanercept
Baseline 34 11.1
3; 11
4.6
1; 7
5.2
2; 6
1.01
0.8; 1.3
58
45; 76
56
40; 75
4.01
3.4; 4.5
26 weeks 19 4.4
2; 5
1
0; 1
1.5
0; 3
0.58
0.3; 0.9
36
15; 54
36
9; 53
2.77
2.2; 3.4
52 weeks 11 8.1
4; 8
1.2
0; 1
1.7
0; 3
0.91
0.5; 1.3
46
33; 52
48
41; 40
3.15
2.6; 3.7
Last visit 44 5.2
1; 6
1.1
0; 1
1.9
0; 3
0.65
0.0; 1.1
36
10; 54
41
14; 64
2.61
1.6; 3.6
Adalimumab
Baseline 15 13.7
4; 16
4.6
2; 6
4.1
2; 6
0.86
0.3; 1.4
57
41; 72
58
51; 77
4.18
3.7; 4.4
26 weeks  12 2.6
1; 4
0.6
0; 0.3
1.5
0; 2
0.70
0.0; 1.5
37
6; 64
39
8; 65
2.67
2.0; 3.3
52 weeks 5 2
0; 3
1.0
0; 0
1.8
0; 0
0.66
0.3; 1.0
29
19; 40
48
45; 59
2.4
1.8; 2.6
Last visit 15 2.8
1; 4
0.7
0; 0.0
2.0
0; 3.5
0.73
0.2; 1.0
40
16; 64
50
28; 76
2.7
1.9; 3.4
p-value** 
between the 
groups
Baseline
26 weeks
52 weeks
Last visit
0.83
0.11
0.17
0.09
0.78
0.31
0.65
0.65
0.43
0.48
0.77
0.63
0.87
0.61
0.58
0.78
0.31
0.34
0.67
0.76
0.16
0.65
0.51
0.44
0.50
0.53
0.44
0.68
Notes: Disease activity at baseline of 185 patients with psoriatic arthritis undergoing four different treatment strategies with TNF-α inhibitors, and on follow-up at 26 and 
52 weeks and at last visit. Data are presented as means and quartiles on the line below. Number is lower than in Table 1 because of missing data. Data are presented as raw 
values without any corrections. No differences were observed between the two infliximab groups evaluated with Wilcoxon test. **Kruskal–Wallis rank sum test was used 
to compare all four groups.
Abbreviations: DAS, Disease Activity Score; Nr, numbers; SJC, swollen 28-joint count; TJC, tender 28-joint count; VAS, visual analog scale; DAS28, .
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200 mg dosage every 8 weeks is less than €8.300. However, 
the dosage is increased in some patients, but only in few 
cases above 5 mg/kg. The mean dosage of infliximab in our 
group of patients with PsA was 277 mg or the equivalent 
of €11.400, which is still lower than if the dosage was the 
internationally recommended 5 mg/kg (€20,600). Several 
other variables need to be considered when performing 
complex economical evaluations. However, the drug cost is 
the single highest cost in this economical equation.  Thus, 
selecting not only TNF inhibitors, but also strictly follow-
ing the dosage with tight follow-up schedules, can save a 
considerable amount of money for the community, as this 
treatment is almost fully reimbursed in Iceland. In addition, 
the Icelandic Social Insurance Administration invites annual 
or biannual tenders that further reduce the cost of biological 
treatment in rheumatology care in Iceland.
The present study has several limitations, as do other 
observational studies. However, the study is based on a 
nationwide clinical registry and reflects routine care and 
clinical decision-making concerning nationwide treatment 
with biologics in patients with PsA. The results strongly 
indicate that a dose lower than 5 mg/kg of infliximab, as 
indicated in several international guidelines, is effective in 
bringing patients with PsA into low stage disease activity 
or remission. However, we must take into consideration the 
fact that our high dose patients will be enriched with patients 
who were non-responders to infliximab. This would tend to 
favor the low dose group in respect to treatment response. 
Furthermore, as this is an observational registry study, there 
are missing values in the registry as well as the fact that we 
do not have reliable data on concomitant medicine such as 
steroids or methotrexate. Therefore, cautious interpretation 
Table 3 Changes in disease activity
Nr D CRP mg/L D SJC D TJC D HAQ D VAS pain D VAS fatigue D DAS28
Infliximab
<4 mg/kg
26 weeks 27
-4.9
-7.0; 0.0
-2.2
-3.3; -0.8
-2.7
-5.0; -0.8
-0.25
-0.4; 0
-21.3
-38; -6.3
-20.1
-39; -0.8
-1.05
-1.7; -0.4
52 weeks 16
-1.8
-8.5; 1.3
-3
-6.5; 0.0
-2.5
-5.0; 0.5
-0.08
-4.4; 0.4
-23.6
-36; 7.5
-12.7
-28; 9.5
-0.81
-1.9; 0.6
Last visit 53
-4.67
-8.3; 1.0
-3.15
-5.0; 0.0
-2.83
-5.0; -1
-0.18
-05; 0.1
-24.2
-50; 7.0
-19.2
-41; 2.8
-1.31
-2.3; -0.5
>4 mg/kg
26 weeks 7 0.71
0.0; 3.5
-2.7
-5.5; -1.0
-4.0
-12; 1.0
-0.21
-0.6; 0.1
-13.9
-14; -2.0
-24.3
-26; -19
-0.9
-2.3; 0.1
52 weeks 2
-5.0
-6.0; -4.0
-15
-2.3; -0.8
0.0
-1.0; 1.0
0.19
0.1; 0.3
-9.5
-17; -2.3
-19.5
-20; -19
-0.7
-1.3; -0.2
Last visit 11
-7.2
-13; -1.3
-2.45
-4.0; 0.0
-5.91
-9.0; 0.0
0.01
-0.3; 0.4
-24.6
-44; -15
29.3
-44; -21
-1.39
-2.8; -0.4
Etanercept
26 weeks 16
-3.8
-5.3;  1.3
-2.6
-5.5; -0.3
-3.0
-5.0; -2.0
0.43
-0.5; 0.4
-20.1
-41; 1.0
-17.2
-36; -1.5
-1.31
-2.1; -0.6
52 weeks 9 2.2
-3.0; 3.0
-2.8
-5.0; -0.5
-2.6
-48; 0
-0.32
-0.4; -0.4
-20
-30; -20
-16.4
-31; -22
-0.65
-0.7; -0.3
Last visit 23
-1.71
-5.0; 1.0
-2.38
-4.3; 0.0
-2
-4.0; 0.0
-0.29
-0.6; -0.1
-21.1
-30; -8.5
-15.4
-31; 11
-1.40
-2.1; 0.7
Adalimumab
26 weeks 10
-4.8
-7.2; -1.3
-4.2
-5.0; -1.5
-3.2
-4.0; -1.5
0.04
0.1; 0.9
-17.5
-43; 9.3
-26.2
-46; -25
-1.4
-1.7; -0.5
52 weeks 4
-4.0
-5.5; -2.5
-3.3
-6.0; 0.0
-4.3
-5; -2.3
-0.38
-0.6; -0.1
-31
-35; -27
-17
-19; -15
-16
-1.7; -1.6
Last visit 15
-4.64
-6.0; -1.5
-3.92
-5.3; 0.0
-2.85
-4.0; -1.0
-047
-0.9; 0.1
-33.0
-57; -5.8
-30.1
-57; -11
-1.90
-2.2; -1.5
p-value**  
between the 
groups
26  weeks
52 weeks
Last visit
0.18
0.37
0.50
0.44
0.97
0.66
0.95
0.58
0.38
022
0.38
0.22
0.81
0.69
0.84
0.93
0.83
0.54
0.94
0.83
0.74
Notes: Changes in disease activity indexes (∆ value) from baseline, of 185 patients with psoriatic arthritis undergoing four different treatment strategies with TNF-α 
inhibitors on follow-up at 26 and 52 weeks and at last visit. Data are presented as means and quartiles on the line below. Number is lower than in Table 2 because of missing 
data. No differences were observed between the two infliximab groups evaluated with Wilcoxon test. **Kruskal–Wallis rank sum test was used to compare all four groups.
Abbreviations: DAS, Disease Activity Score; Nr, numbers; SJC, swollen 28-joint count; TJC, tender 28-joint count; HAQ, ; VAS, visual analog scale; DAS28, .
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is advised when comparing the results of the present study. 
Therefore, the present findings show the need for further 
research by designing a multicenter, randomized controlled 
trial, where radiological follow-up of joint damage should 
be included and with at least two parallel arms with both 
the recommended doses of infliximab, i.e., 5 mg/kg, as well 
as some other TNF inhibitors, i.e., etanercept, adalimumab, 
golimumab or certolizumab. In addition, long-term follow-
up studies are needed to describe drug survival, drug toler-
ance and effectivity in respect to a lower dose approach of 
infliximab in comparison to the 5 and 10 mg/kg body weight 
that has already been described in the IMPACT studies.5,6 
Future studies should also include the economic aspect of 
the issue.
Interestingly, two observations that increase the validity 
of the present results are: firstly, those patients who needed 
to escalate their infliximab dose above 4 mg/kg had a sig-
nificantly lower mean body weight compared to those who 
responded to the lower dosage. Thus, it was not the fact 
that patients were overweight, which has frequently been 
described in patients with psoriasis16 and PsA,17 which drove 
the escalation of the infliximab dosage. Secondly, and to 
our surprise to some extent, the disease activity at baseline 
evaluated with CRP, number of tender and swollen joints as 
well as the VAS of pain and fatigue, was similar in all four 
treatment groups, as if this was a randomized controlled trial, 
even though it was not. 
In respect to treatment effects, a low dosage of infliximab 
with possible escalating dosage is acceptable for the majority 
of PsA patients who are in need of biological treatment, and as 
effective as standard doses of adalimumab and etanercept in 
patients with PsA. Drug selection can influence the economic 
burden of biological treatment in PsA.
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